Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​July policy updates

August 5, 2022

​In July, Independence Blue Cross updated several policies. Published updates include:

  • 08.00.85m: Tocilizumab (Actemra®) for Intravenous Infusion. Effective date: July 18, 2022
  • 08.01.94: Nivolumab and relatlimab-rmbw (Opdualag™). Effective date: July 18, 2022

To view the latest medical and claim payment policy bulletins, visit the Medical and Claim Payment Policy P​ortal.

For important policy information related to COVID-19, visit the Commercial and Medicare Advantage News & Announcements sections of the portal.

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.